Quantitative positron emission tomography studies of the serotonin transporter in humans previously treated with the appetite suppressants fenfluramine or dexfenfluramine

Molecular Imaging and Biology

Volumn 9, Issue 3, 2007, Pages 151-157

  McCann, Una D ^a   Szabo, Zsolt ^a   Vranesic, Melin ^a   Seckin, Esen ^a   Wand, Gary ^a   DuVal, Anna ^a   Dannals, Robert F ^a   Ricaurte, George A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amphetamines; Neurotoxicity; Serotonin

Indexed keywords

1,2,3,5,6,10B HEXAHYDRO 6 (4 METHYLTHIOPHENYL)PYRROLO[2,1 A]ISOQUINOLINE C 11; DEXFENFLURAMINE; FENFLURAMINE; RADIOPHARMACEUTICAL AGENT; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG EXPOSURE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SUBSTITUTION; DRUG UPTAKE; DRUG WITHDRAWAL; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; IMAGE RECONSTRUCTION; MALE; NEUROTOXICITY; OBESITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOACTIVITY;

ADULT; AGED; ANIMALS; APPETITE DEPRESSANTS; BRAIN; CARBON RADIOISOTOPES; CASE-CONTROL STUDIES; DEXFENFLURAMINE; FEMALE; FENFLURAMINE; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

ANIMALIA; PRIMATES;

EID: 34248224268     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-007-0082-7     Document Type: Article

References (42)

1. Colman E (2005) Anorectics on trial: A half-century of federal regulation of prescription appetite suppressants. Ann Intern Med 143:380-385
2. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV (1997) Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337:581-588. Erratum in: N Engl J Med 337:1783 (1997 Aug 28)
3. Harvey J, McMaster S (1975) Fenfluramine: Evidence for a neurotoxic action on midbrain and a long-term depletion of serotonin. Psychopharmacol Commun 1:217-228
4. Sanders-Bush E, Bushing JA, Sulser F (1975) Long-term effects of p-chloroamphetamine and related drugs on central serotonergic mechanisms. J Pharmacol Exp Ther 192:33-41
5. Harvey J, McMaster S, Fuller R (1977) Comparison between the neurotoxic and serotonin depleting effects of various halogenated derivatives of amphetamine in the rat. J Pharmacol Exp Ther 202:581-589
6. Clineschmidt B, Zachel A, Totaro J, Pflueger A, McGuffin J (1978) Fenfluramine and brain serotonin. Ann NY Acad Sci 305:222-241
7. Schuster CR, Lewis M, Seiden L (1986) Fenfluramine: Neurotoxicity. Psychopharmacol Bull 22:148-151
8. Kleven MS, Schuster CR, Seiden LS (1988) Effects of depletion of brain serotonin by repeated fenfluramine on neurochemical and anorectic effects of acute fenfluramine. J Pharmacol Exp Ther 246:822-828
9. Kleven MS, Seiden LS (1989) D-,L-, DL-fenfluramine cause long lasting depletions of serotonin in rat brain. Brain Res 505:351-353
10. Appel NM, Contrera JF, De Souza EB (1990) Fenfluramine selectively and differentially decreases the density of serotonergic nerve terminals in rat brain: Evidence from immunocytochemical studies. J Pharmacol Exp Ther 249:928-943
11. Johnson MP, Nichols DE (1990) Comparative serotonin neurotoxicity of the stereoisomers of fenfluramine and norfenfluramine. Pharmacol Biochem Behav 36:105-109
12. Molliver DC, Molliver ME (1990) Anatomic evidence of a neurotoxic effect of (-) fenfluramine upon serotonergic projections in the rat. Brain Res 511:165-168
13. Zaczek R, Battaglia G, Culp S, Appel NM, Contrera JF, De Souza EB (1990) Effects of repeated fenfluramine administration on indexes of monoamine function in rat brain: Pharmacokinetic, dose response, regional specificity and time-course data. J Pharmacol Exp Ther 253:104-112
14. Caccia S, Aneli M, Ferrrese A, Fracaso C, Garattini S (1993) The role of d-norfenfluramine in the indole-depleting effect of fenfluramine. Eur J Pharmacol 233:71-77
15. Westphalen R, Dodd P (1995) The nature of D-L-induced 5-HT re-uptake transporter loss in rats. Mol Neurobiol 11:165-175
16. McCann U, Hatzidimitriou G, Ridenour A, Fischer C, Yuan J, Katz J, Ricaurte G (1994) Dexfenfluramine and serotonin neurotoxicity: Further preclinical evidence that clinical caution is indicated. J Pharmacol Exp Ther 269:792-798
17. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA (1998) Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet 352:1433-1437
18. McCann UD, Szabo Z, Seckin E, Rosenblatt P, Mathews WB, Ravert HT, Dannals RF, Ricaurte GA (2005) Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11 C]McN5652 and [11 C]DASB. Neuropsychopharmacology 30:1741-1750
19. Buchert R, Thomasius R, Nebeling B, Petersen K, Obrocki J, Jenicke L, Wilke F, Wartberg L, Zapletalova P, Clausen M (2003) Long-term effects of "ecstasy" use on serotonin transporters of the brain investigated by PET. J Nucl Med 44:375-384
20. Buchert R, Thomasius R, Wilke F, Petersen K, Nebeling B, Obrocki J, Schulze O, Schmidt U, Clausen M (2004) A voxel-based PET investigation of the long-term effects of "Ecstasy" consumption on brain serotonin transporters. Am J Psychiatry 161:1181-1189
21. Scheffel U, Szabo Z, Mathews WB, Finley PA, Dannals RF, Ravert HT, Szabo K, Yuan J, Ricaurte GA (1998) In vivo detection of short-and long-term MDMA neurotoxicity-a positron emission tomography study in the living baboon brain. Synapse 29(2):183-192
22. Szabo Z, McCann UD, Wilson AA, Scheffel U, Owonikoko T, Mathews WB, Ravert HT, Hilton J, Dannals RF, Ricaurte GA (2002) Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions. J Nucl Med 43:678-692
23. Scheffel U, Szabo Z, Mathews WB, Finley PA, Yuan J, Callahan B, Hatzidimitriou G, Dannals RF, Ravert HT, Ricaurte GA (1996) Fenfluramine-induced loss of serotonin transporters in baboon brain visualized with PET. Synapse 24(4):395-398
24. Szabo Z, Scheffel U, Mathews WB, Ravert HT, Szabo K, Kraut M, Palmon S, Ricaurte GA, Dannals RF (1999) Kinetic analysis of [11 C]McN5652: A serotonin transporter radioligand. J Cereb Blood Flow Metab 19:967-981
25. Wilson AA, Ginovart N, Schmidt M, Meyer JH, Threlkeld PG, Houle S (2000) Novel radiotracers for imaging the serotonin transporter by positron emission tomography: Synthesis, radiosynthesis, and in vitro and ex vivo evaluation of (11)C-labeled 2(phenylthio)araalkylamines. J Med Chem 43:310-311
26. Hilton J, Yokoi F, Dannals RF, Ravert HT, Szabo Z, Wong DF (2000) Column-switching HPLC for the analysis of plasma in PET imaging studies. Nucl Med Biol 27:627-630
27. Szabo Z, Owonikoko T, Peyrot M, Varga J, Mathews WB, Ravert HT, Dannals RF, Wand G (2004) Positron emission tomography imaging of the serotonin transporter in subjects with a history of alcoholism. Biol Psychiatry 55:766-771
28. Varga J, Szabo Z (2002) A modified regression model for the Logan plot. J Cereb Blood Flow Metab 22:240-244
29. Frankle WG, Huang Y, Hwang DR, Talbot PS, Slifstein M, Van Heertum R, Abi-Dargham A, Laruelle M (2004) Comparative evaluation of serotonin transporter radioligands 11C-DASB and 11C-McN 5652 in healthy humans. J Nucl Med 45:682-694
30. Murphy DL, Andrews AM, Wichems CH, Li O, Tohda M, Greenberg B (1998) Brain serotonin neurotransmission: An overview and update with an emphasis on serotonin subsystem heterogeneity, multiple receptors, interactions with other neurotransmitter systems, and consequent implications for understanding the actions of serotonergic drugs. J Clin Psychiatry 59:4-12, Review
31. Arango V, Underwood MD, Mann JJ (2002) Serotonin brain circuits involved in major depression and suicide. Prog Brain Res 136:443-453, Review
32. Hornung JP (2003) The human raphe nuclei and the serotonergic system. J Chem Neuroanat 26:331-343, Review
33. Golding D (1970) Unusual effect of fenfluramine. Br Med J 1:238
34. Oswald I, Lewis SA, Dunleavy DLF, Brezinova V, Briggs M (1970) Drugs of dependence though not of abuse. Br Med J 3:70-73
35. Harding T (1971) Fenfluramine dependence. Br Med J 2:305
36. Harding T (1972) Depression following fenfluramine withdrawal. Br J Psychiatry 121:338-339
37. Toornvliet AC, Pijl H, Meinders AE (1994) Major depression during dexfenfluramine treatment. Int J Obesity 18:650
38. Raison CL, Klein HM (1997) Psychotic mania associated with fenfluramine and phentermine use. Am J Psychiatry 154:711
39. Preval H, Palyurek AM (1997) Psychotic episode associated with dexfentluramine. Am J Psychiatry 154:1624-1625
40. Verbaten MN (2003) Specific memory deficits in ecstasy users. The results of a meta-analysis. Hum Psychopharmacol 18:281-290
41. Staley JK, Krishnan-Sarin S, Zoghbi S, Tamagnan G, Fujita M, Seibyl JP, Maciejewski PK, O'Malley S, Innis RB (2001) Sex differences in [123I]beta-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse 41:275-284
42. Staley JK, Sanacora G, Tamagnan G, Maciejewski PK, Malison RT, Berman RM, Vythilingam M, Kugaya A, Baldwin RM, Seibyl JP, Charney D, Innis RB (2006) Sex differences in diencephalon serotonin transporter availability in major depression. Biol Psychiatry 59:40-47